Jounce therapeutics, inc. (JNCE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Operating activities:
Net loss

56,823

-27,379

-16,443

-13,703

-28,532

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

9,609

9,407

4,775

4,989

1,352

Depreciation expense

3,900

3,800

4,400

1,944

1,470

Change in other financing income, net

-

-

-

0

1,859

Net amortization of premiums and discounts on investments

1,480

1,107

-1,172

-327

0

Loss on disposal of property and equipment

-

-

-75

0

0

Changes in operating assets and liabilities:
Taxes receivable

0

-16,737

0

-

-

Prepaid expenses and other current assets

1,375

-873

17,416

1,979

23

Other non-current assets

728

0

266

527

99

Accounts payable

-944

562

373

-312

673

Accrued expenses and other current liabilities

1,983

-1,443

4,120

953

1,929

Deferred revenue—related party

-97,872

-65,201

-71,644

-

-

Other liabilities

4

107

-

-

-

Deferred revenuerelated party

-

-

-

187,804

0

Other non-current liabilities

-

-

-

0

-28

Deferred rent

-

-

-156

192

-622

Net cash used in operating activities

-30,129

-63,613

-90,988

179,688

-25,739

Investing activities:
Purchases of investments

188,999

252,918

179,874

213,286

0

Proceeds from maturities of investments

221,366

336,694

141,322

0

0

Proceeds from sales of investments

0

3,997

15,638

-

-

Proceeds from sales of investments

-

-

-

0

0

Purchases of property and equipment

985

1,359

15,107

2,222

2,202

Change in restricted cash

-

-

-

0

-60

Net cash provided by investing activities

31,382

86,414

-38,021

-215,508

-2,142

Financing activities:
Proceeds from at the market offering, net of issuance costs

3,645

0

-

-

-

Proceeds from initial public offering of common stock, net of issuance costs

-

-

107,008

0

0

Proceeds from exercise of stock options

-

-

462

50

112

Proceeds from exercise of stock options

437

1,546

-

-

-

Cash paid for issuance costs

-

-

-

620

241

Net cash provided by financing activities

4,082

1,546

107,470

35,507

70,704

Net increase (decrease) in cash, cash equivalents and restricted cash

5,335

24,347

-21,539

-

-

Non-cash investing and financing activities:
Net (decrease) increase in cash and cash equivalents

-

-

-

-313

42,823

Non-cash investing and financing activities:
Accretion of convertible preferred stock to redemption value

-

-

-

0

1,011

Reclassification of tranche rights upon issuance of preferred stock

-

-

-

0

1,725

Purchases of property and equipment in accounts payable and accrued expenses

29

31

170

1,870

22

Issuance costs in accounts payable and accrued expenses

134

0

-

850

1,580

Supplemental cash flow information:
Cash paid for lease liabilities

4,270

0

-

-

-

Cash paid for income taxes

101

0

16,750

0

0